Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report
This case highlights the clinical relevance of golidocitinib in developing novel therapeutic strategies for NK-LGLL. Moreover, this treatment option presents the potential as either a bridging therapy or alternative to allo-HSCT.
Authors
- Hongyuan Hao
- Jimo Jian (ORCID: https://orcid.org/0000-0002-8471-0039)
- Chen Zhang (ORCID: https://orcid.org/0000-0002-5080-9321)
- Chenglu Yuan
Institutions
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1632803
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Natural Science Foundation of Shandong Province